The Peptide AppThe Peptide App

The Peptide AppField Guide · Metabolic SeriesSpecimen No. 12

Metabolic Category

Apelin-12

THE HEART OPTIMIZER

Pyr¹-Apelin-13 (short isoform), Apelin fragment 12

Apelin-12 is a naturally occurring peptide that acts as a powerful cardiovascular regulator. It improves blood flow, strengthens heart contractions, and enhances how your body processes glucose - all without increasing oxygen demand on the heart. It's being studied for heart failure, metabolic syndrome, and as an anti-aging compound.

Apelin-12
Apelin-12
Apelin-12

Apelin-12 Evidence Snapshot

How these guides are reviewed
Regulatory status
Not FDA approved · research use only
Dosing guidance
Reviewed by our clinical team
Linked evidence
7 research sources
Content updated
May 8, 2026

Dose and schedule recommendations shown below come from The Peptide App Clinical Team. Research links are provided so readers can inspect the supporting evidence directly. Review the sources.

Quick Answers About Apelin-12

Is Apelin-12 FDA approved?

No. This profile records Apelin-12 as not FDA approved and for research use only.

More context

Review the regulatory and source details on this page for the current context.

What dose does The Peptide App Clinical Team recommend for Apelin-12?

Dose: 0.5-1 mg weekly (fractionated doses).

More context

Schedule: daily. Cycle: Ongoing or as needed. This is clinical-team guidance for reference and does not replace individualized instructions from a licensed clinician.

What research supports this Apelin-12 guide?

This guide links to 7 curated or current research sources.

More context

Open the research section to inspect the source titles, publication details, study types, and available abstracts directly.

Review the Apelin-12 research sources

Studied Effects & Mechanisms

Heart Strengthener

Increases cardiac output without raising oxygen demand

Vasodilation

Relaxes blood vessels for improved circulation

Glucose Uptake

Enhances how cells absorb and use glucose

Anti-Oxidant

Reduces inflammation and oxidative damage in blood vessels

Clinical & Research Context

People with cardiovascular concerns
Those wanting to improve metabolic flexibility
Aging individuals focused on heart health
Athletes seeking improved endurance
Anyone with poor circulation

Research-Market Price Snapshot

A compact market signal for this profile. The dedicated pricing page owns vendor, vial-size, and price-per-mg comparisons.

Live pricing

The live pricing feed did not return ready in-stock rows for this peptide.

Open the dedicated pricing page →

Apelin-12 Research

Live PubMed intelligence from the research crawler

PMID 27899856HumanRelevance 82Extracted

BACKGROUND: The aim of this study was to determine whether spironolactone therapy has an effect on serum apelin-12 levels in heart failure with reduced ejection fraction (HFrEF) patients. METHODS: Eighty outpatients previously diagnosed with HFrEF were enrolled in the current study. Included patients were taking only standard heart failure therapy (ST) (angiotensin converting enzyme or angiotensin receptor blocker, beta-blockers, loop diuretics and anticoagulant or antiagregan agents) without a mineralocorticoid receptor antagonists (MRA) because of its side effects, and were designated the non-MRA group; those patients taking 25 mg/daily spironolactone in addition to the ST were deemed the MRA group. Patient blood samples were collected to measure serum apelin-12 levels. RESULTS: After adjustment for all clinical and demographic factors, plasma apelin-12 levels were significantly higher and NT pro-BNP levels were significantly lower in the MRA group compared to the non-MRA group (p < 0.001, p < 0.001; respectively). In multiple linear regression analyses, there was no association between baseline apelin-12 level and clinical parameters. MRA using initial apelin-12 levels were lower and NT pro-BNP levels were higher in patients with stricken event than in event-free patients (p = 0.042, p < 0.001, and p < 0.001; respectively). CONCLUSIONS: Blocking the aldosterone receptors by spironolactone, in addition to maximal standard therapy, may increase serum apelin-12 levels among patients with HFrEF.

Dosing evidenceSafety evidenceEfficacy evidence
PMID 33725773HumanRelevance 80Extracted

BACKGROUND: To analyze the expression levels of plasma dimethylglycine (DMG), human maternally expressed gene 3 (MEG3), and Apelin-12 in patients with acute myocardial infarction (AMI) and explore their clinical significance. METHODS: One hundred and ten patients with suspected AMI (chest pain duration <6 h) who were admitted to our hospital between December 2018 and June 2020 were included. Plasma DMG, MEG3, and Apelin-12 levels were measured at the time of admission. The levels of plasma DMG, MEG3, and Apelin-12, as well as the general data and admission baseline data of these patients were then compared with those of non-AMI patients. The receiver operating characteristic (ROC) curve was used to analyze the clinical value of plasma DMG, MEG3, and Apelin-12 levels for the early diagnosis of AMI. RESULTS: Among the 110 patients with chest pain suspected of AMI, 34 were clinically diagnosed with AMI, and 76 were non-AMI patients. The proportion of males, smoking, history of myocardial infarction, and congestive heart failure in the AMI group were higher than those of the non-AMI group. The proportions of systolic blood pressure (SBP), ST-segment elevation, and electrocardiogram (ECG) dynamic changes on admission were also higher in the AMI group compared to those of the non-AMI group (P<0.05). The plasma DMG, MEG3, and Apelin-12 levels of patients in the AMI group on admission were higher than those of the non-AMI group (P<0.05); all have diagnostic value for AMI upon admission. The area under the curve (AUC) of MEG3 was higher than that of both DMG and Apelin-12, however the difference was not statistically significant (Z=1.378, 0.934, P=0.168, 0.350). Using 0.015 as the cut-off value for MEG3-messenger ribonucleic acid (mRNA), the sensitivity and specificity for diagnosing AMI were 85.29% and 81.58%, respectively. CONCLUSIONS: Our results showed that the plasma levels of DMG, MEG3, and Apelin-12 in patients with AMI were high, and thus, they can be used as biomarkers for the early diagnosis of AMI. Among them, MEG3 was the most effective in early diagnosing AMI.

Efficacy evidence
PMID 35847238HumanRelevance 79Extracted

BACKGROUND: Apelin-12 and estimated glomerular filtration rate (eGFR) are considered prognostic factors for ST-segment elevation myocardial infarction (STEMI). However, little is known about whether the combined use of these two biomarkers could enhance the prognostic value. This study aimed to investigate the utility of combining apelin-12 and eGFR for STEMI. METHODS: Patients were divided into four groups based on median apelin-12 level and eGFR level: A: low apelin-12, low eGFR; B: low apelin-12, high eGFR; C: high apelin-12, low eGFR; and D: high apelin-12, high eGFR. The Cox regression was used to identify prognostic factors. The Kaplan-Meier and the receiver operating characteristic (ROC) curves were generated to evaluate the prognostic value of apelin-12 combined with eGFR in patients with STEMI. RESULTS: Among 460 patients, 118 (25.7%) experienced major adverse cardiac events (MACEs) during the entire follow-up of 30 months. The Kaplan-Meier curve analysis revealed that group D had the best prognosis compared with the other three groups. The combination of apelin-12 and eGFR (area under the ROC curve (AUC), 0.699) enhanced the predictive value for MACE compared with either apelin-12 (AUC, 0.617) or eGFR (AUC, 0.596) alone. There was a negative association between apelin-12 and eGFR (r = -0.32, p < 0.001), while no association was observed between the Gensini score and apelin-12 or eGFR. CONCLUSIONS: This study suggests that both low apelin-12 (<0.76 ng/ml) and low eGFR (<94.06 mL/min/1.73 m2) are associated with poor prognosis in STEMI, indicating that the combination of apelin-12 and eGFR could enhance the prognostic value of patients with STEMI.

Efficacy evidence
PMID 37171284HumanRelevance 78Extracted

BACKGROUND: Acute myocardial infarction is characterised by an imbalance in the supply and demand of oxygen in the heart. It requires urgent reperfusion, and poor outcomes are attributed to myocardial ischaemia-reperfusion injury. We aimed to evaluate the association between apelin-12 levels and creatine kinase-MB activity in predicting the effectiveness of reperfusion therapy in ST-segment elevation myocardial infarction (STEMI) patients. METHODS: In this study we included 72 patients with the following criteria: chest pain suggestive of myocardial ischaemia for at least 30 minutes, an electrocardiogram with ST-segment elevation (measured at the J-point) ≥ 2 mm in leads V2-V3 and/or ≥ 1 mm in the other leads, rise of specific biomarkers such as cardiac troponin and the MB fraction of creatine kinase (CK-MB), and those who underwent reperfusion therapy. Blood samples for the measurement of apelin-12 and creatine kinase-MB were collected 12 hours after the reperfusion therapy. RESULTS: In patients with thrombolysis in myocardial infarction (TIMI) flow grade ≤ 2, the median of the apelin-12 level was 1.80 ng/ml (0.46-9.20), and with TIMI flow 3, it was 5.76 ng/ml (1.14-15.2). Variability was observed in the apelin values (Mann-Whitney test) based on TIMI flow grade (p < 0.001), while no variability was observed for creatine kinase-MB (p < 0.18). The degree of association between apelin-12 and creatine kinase-MB levels was analysed with Pearson's correlation, enabling us to determine patients with successful reperfusion (determined as TIMI flow 3) (p < 0.004), and those with unsuccessful reperfusion (with TIMI flow ≤ 2) (p = 0.86). CONCLUSION: In STEMI patients undergoing reperfusion therapy, Apelin-12 level was associated with creatine kinase-MB activity according to the success of the reperfusion.

Efficacy evidence
PMID 32380198HumanRelevance 78Extracted

Chemically modified peptide apelin-12 ([MeArg1, NLe10]-apelin12, peptide M) is able to reduce reactive oxygen species (ROS) formation, cell death, and metabolic and ionic homeostasis disorders in experimental myocardial ischemia-reperfusion injury. These beneficial effects indicate the therapeutic potential of this compound in cardiovascular diseases. The goals of this work were to optimize the synthesis of peptide M, and to study its proteolytic stability and effect on the heart function of rabbits with doxorubicin (Dox) cardiomyopathy. We have developed a rational method of solid-phase synthesis of peptide M using the Fmoc methodology in combination with the temporary protection of the guanidine function of arginine residues by protonation (salt formation) during the formation of the amide bond. It avoids the formation of by-products, and simplifies the post-synthetic procedures, providing an increase in the yield of the final product of higher purity. Comparative evaluation of the proteolytic stability of peptide M and apelin-12 in human blood plasma was carried out using 1H NMR spectroscopy. It was shown that the half-life of peptide M in plasma is approximately three times longer than that of apelin-12. Intravenous infusion of increasing doses of peptide M caused a gradual increase in left ventricular (LV) fractional shortening and ejection fraction in rabbits after 8 weeks of Dox administration (2 mg/kg weekly). The effect of the modified peptide on LV systolic dysfunction was significantly more pronounced than the effect of apelin-12, which suggests the promise of using this pharmacological agonist of the APJ receptor in patients with heart failure.

Dosing evidenceEfficacy evidence
PMID 41211732AnimalRelevance 77Extracted

The use of pharmacological agents to trigger preconditioning mechanisms may improve the prevention and treatment of coronary heart disease. The aim of this study was to evaluate the ability of a structural analog of apelin-12 ((NαMe)Arg-Pro-Arg-Leu-Ser-His-Lys-Gly-Pro-Nle-Pro-Phe-OH, metilin) to reproduce the effect of ischemic preconditioning (IP) of rat hearts in vivo. Control rats were exposed to 40-min occlusion of the left descending coronary artery (LDCA) followed by 60-min restoration of coronary blood flow (reperfusion). IP was modeled by three cycles of 5-min occlusion/5-min reperfusion of the LDCA before prolonged regional myocardial ischemia and reperfusion. Metilin (5 mg/kg) was administered to rats intravenously by bolus injection 30 min before LDCA occlusion. IP or metilin had a significant impact on the studied parameters. The size of necrotic damage to the left ventricle, expressed as the percentage ratio of myocardial infarction/myocardial area at risk (MI/AAR, %), at the end of reperfusion was 26.9±2.0% and 29.3±2.6%, respectively, compared with 43.8±1.2% in the control (p < 0.01). The activity of creatine kinase-MB (CK-MB) in blood plasma decreased to 1026.1±93.9 IU/ml and 1195.2±142.0 IU/ml, respectively, compared with 1986.3±193.7 IU/ml in the control (p < 0.02). Administration of metilin, as well as IP, increased the reduced content of ATP, total adenine nucleotide pool (ΣAN) and phosphocreatine (PCr) in the AAR at the end of reperfusion compared to the control (p < 0.05-0.01). In the metilin group, the content of total creatine (ΣCr) in AAR was higher than in the control (p < 0.05). Intravenous administration of 5 mg/kg 5-hydroxydecanoate (5HD), an inhibitor of mitochondrial ATP-dependent K+ channels (mitoKATP), abolished the preconditioning effect of metilin, and increased the MI/AAR, %, and plasma CK-MB activity to values that insignificantly differed from the control (39.4±2.8% and 2258.2±179.1 IU/ml, respectively). Simultaneously, 5HD significantly reduced the ATP and ΣAN levels in AAR compared to those in the metilin group and the ATP, ΣAN, and PCr levels compared to the IP group. The results indicate that pharmacological preconditioning by metilin reduced cardiac ischemia/reperfusion injury via the involvement of mitoKATP in the mechanism of metilin action.

Dosing evidenceSafety evidenceEfficacy evidence

Related Peptides

SS-31

THE MITOCHONDRIAL OPTIMIZER
BGood
Cardiovascular Support · Neurological SupportHealing · Cardiovascular SupportDose5 mgCycle6 weeks on, 8 weeks offKicks inEnergy improvements may be noticed within...

Directly target and repair your mitochondria

from $1.60/mg · 53 vendorsNº 003 / 006

AICAR

THE EXERCISE MIMETIC
CModerate
Metabolic Modulator · Weight ManagementMetabolic · Metabolic ModulatorDoseSee guideCycle4-6 weeks on, 2-4 weeks offKicks inMetabolic improvements can be measured...

Exercise in a molecule - activate your metabolism without the gym

from $0.76/mg · 6 vendorsNº 001 / 006

L-Carnitine

THE FAT TRANSPORTER
AHigh
Metabolic Modulator · Mitochondrial SupportMetabolic · Metabolic ModulatorDoseSee guideCycleOngoing or as neededKicks inEnergy improvements often noticed within 1-2...

Fat-burning amino acid for energy and mitochondrial health

from $0.03/mg · 9 vendorsNº 002 / 006

Svetinorm

THE LIVER CLEANSER
AHigh
Metabolic Modulator · Anti-InflammatoryHealing · Metabolic ModulatorDoseSee guideCycle4 weeks on, 12 weeks offKicks inLiver enzyme improvements may be measurable...

Restore liver health and optimize detoxification

Full profileNº 004 / 006

Ventfort

THE ARTERY RESTORER
BGood
Cardiovascular Support · Anti-Aging & LongevityLongevity · Cardiovascular SupportDoseSee guideCycle4 weeks on, 12 weeks offKicks inCirculation improvements typically noticed...

Restore arterial health and vascular flexibility

Full profileNº 005 / 006

Vesugen

THE VESSEL PROTECTOR
BGood
Cardiovascular Support · Anti-Aging & LongevityCognitive · Cardiovascular SupportDoseSee guideCycle4 weeks on, 12 weeks offKicks inVascular improvements typically noticed...

Protect and restore your blood vessel lining

from $1.60/mg · 13 vendorsNº 006 / 006